BioCentury
ARTICLE | Clinical News

Guardant's liquid biopsy is faster, as effective as tissue biopsy

March 1, 2019 7:56 PM UTC

Guardant Health Inc. (NASDAQ:GH) said its Guardant360 liquid biopsy detected biomarkers at a similar rate as standard-of-care tissue genotyping tests, but faster. Data were presented at a media preview ahead of the American Association for Cancer Research (AACR) meeting in Atlanta.

The NILE study evaluated Guardant360's ability to detect seven predictive biomarkers -- EGFR, ALK, ROS1, BRAF, RET, c-MET and HER2 -- and the prognostic biomarker KRAS in 282 non-small cell lung cancer (NSCLC) patients...